


Anticancer agent 106

Cat. No.:	HY-149950
CAS No.:	3009090-13-2
Molecular Formula:	C ₂₆ H ₂₅ N ₃ O ₄ S
Molecular Weight:	475.56
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Anticancer agent 106 (compound 10ic) is an anticancer agent that induces apoptosis in B16-F10 melanoma cells. Anticancer agent 106 also potently inhibits metastatic nodules in a mouse model of lung metastatic melanoma. Anticancer agent 106 can be used in the study of cancer, especially lung metastatic melanoma ^[1] .																
In Vitro	<p>Anticancer agent 106 (compound 10ic; 0.28-55 μM; 24 h) reduces the viability of B16-F10 melanoma cells in a dose-dependent manner, with an IC₅₀ value of 4.8 μM^[1].</p> <p>Anticancer agent 106 (5-20 μM; 48 h) induces apoptosis of B16-F10 melanoma cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>B16-F10 melanoma cells</td> </tr> <tr> <td>Concentration:</td> <td>0.28-55 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited B16-F10 melanoma cells in a dose-dependent manner (IC₅₀ = 4.8 μM).</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>B16-F10 melanoma cells</td> </tr> <tr> <td>Concentration:</td> <td>5-20 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Induced cell apoptosis.</td> </tr> </table>	Cell Line:	B16-F10 melanoma cells	Concentration:	0.28-55 μ M	Incubation Time:	24 h	Result:	Inhibited B16-F10 melanoma cells in a dose-dependent manner (IC ₅₀ = 4.8 μ M).	Cell Line:	B16-F10 melanoma cells	Concentration:	5-20 μ M	Incubation Time:	48 h	Result:	Induced cell apoptosis.
Cell Line:	B16-F10 melanoma cells																
Concentration:	0.28-55 μ M																
Incubation Time:	24 h																
Result:	Inhibited B16-F10 melanoma cells in a dose-dependent manner (IC ₅₀ = 4.8 μ M).																
Cell Line:	B16-F10 melanoma cells																
Concentration:	5-20 μ M																
Incubation Time:	48 h																
Result:	Induced cell apoptosis.																
In Vivo	<p>Anticancer agent 106 (9-9.5 mg/kg; i.p.; every 3rd d for 22 d) inhibits the metastatic nodules in pulmonary metastatic melanoma mouse model^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>B16-F10 melanoma-bearing C57BL/6 mice (pulmonary metastatic melanoma model)^[1].</td> </tr> </table>	Animal Model:	B16-F10 melanoma-bearing C57BL/6 mice (pulmonary metastatic melanoma model) ^[1] .														
Animal Model:	B16-F10 melanoma-bearing C57BL/6 mice (pulmonary metastatic melanoma model) ^[1] .																

Dosage:	9-9.5 mg/kg
Administration:	Intraperitoneal administration; every 3rd d for 22 d.
Result:	Inhibited the lung metastases.

REFERENCES

[1]. Anna Rogova, et al. Synthesis of thieno[3,2-e]pyrrolo[1,2-a]pyrimidine derivatives and their precursors containing 2-aminothiophenes fragments as anticancer agents for therapy of pulmonary metastatic melanoma. Eur J Med Chem. 2023, 254: 115325.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA